Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2024-09-04 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
关于实际控制人部分股份质押及解除质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the pledge and release of shares by its actual controllers and major shareholders. It details the number of shares pledged, released, and the related terms. There is no financial statement, earnings data, or management discussion. The content focuses on share pledging activities by controlling shareholders, which is a capital structure related update. The document length is 3544 characters, which is relatively short and typical for a capital/financing update announcement. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2024-09-04 Chinese
关于高级管理人员增持股份计划实施完毕的公告
Director's Dealing Classification · 95% confidence The document is an announcement regarding the completion of a share purchase plan by senior management personnel of the company. It details the shareholding changes of two executives, including the number of shares purchased, the timing, and the compliance with relevant laws and regulations. There is no financial report, earnings data, or management discussion of financial results. The document focuses on insider share transactions by company directors and executives. Therefore, it fits the category of Director's Dealing (DIRS). The document length is 2706 characters, which is consistent with a detailed announcement but not a full financial report.
2024-08-29 Chinese
中信证券股份有限公司关于重庆博腾制药科技股份有限公司调整部分募集资金投资项目计划进度的核查意见
Capital/Financing Update Classification · 95% confidence The document is a verification opinion from a sponsoring institution (中信证券股份有限公司) regarding the adjustment of the progress schedule of certain fundraising investment projects by 重庆博腾制药科技股份有限公司. It references regulatory requirements related to fundraising and investment project management, details the use and adjustment of fundraising project timelines, and includes approvals from the board and supervisory committee. The document is not a full financial report but rather a formal verification and opinion on fundraising project progress adjustments. It does not contain comprehensive financial statements or quarterly/yearly financial results. The document length is about 2082 characters, which is relatively short and focused on a specific regulatory compliance matter related to fundraising project progress. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2024-08-27 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Chongqing Boteng Pharmaceutical Technology Co., Ltd. regarding a change in accounting policies following new accounting standards issued by the Ministry of Finance (specifically Interpretation No. 17). It details the reasons for the change, the effective date, the previous and new accounting policies, and the impact on the company. The document is relatively short (1064 characters) and is an announcement of a policy change approved by the board, not a full financial report or audit report. It does not contain financial statements or detailed financial analysis. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about accounting policy changes without substantive financial data or a full report attached.
2024-08-27 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2024 年半年度报告摘要" which translates to "2024 Semi-Annual Report Summary." It contains detailed financial data for the half-year period, including revenue, net profit, segment performance, shareholder information, and operational highlights. The document is about 8,295 characters long, which is substantial and contains actual financial figures and analysis, not just an announcement or a brief summary. The content includes comprehensive financial and operational data typical of an Interim / Quarterly Report. There is no indication that this is a full Annual Report (10-K) or just an announcement of a report publication. It is not a call transcript, audit report, or any other category. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2024-08-27 Chinese
总经理工作细则（2024年8月）
Board/Management Information Classification · 95% confidence The document is titled '总经理工作细则' (General Manager Work Rules) for 重庆博腾制药科技股份有限公司, dated August 2024. It details the roles, responsibilities, appointment, dismissal, and authority of the company's general manager and other senior management personnel. It includes procedural rules, reporting requirements, and performance evaluation criteria for management. There is no financial data, no audit information, no voting results, no legal proceedings, no capital changes, no earnings data, no presentations, and no regulatory filings. The document is a detailed internal management guideline or policy document related to the company's board/management structure and management roles. This fits best under the category 'Board/Management Information (MANG)', which covers announcements or documents about changes or rules regarding the company's board or senior management. The document is not a report or announcement of a report but a detailed internal management rule set. Therefore, the classification is MANG with high confidence.
2024-08-27 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.